Endothelial cells synthesize prostacyclin (PGI 2 ), an unstable prostaglandin that inhibits platelet aggregation and serotonin release. Because cyclooxygenase, which is necessary for synthesis of PGI 2 , is inactivated by aspirin, we examined the effect of aspirin on PGI 2 production by cultured human endothelial cells. Endothelial cells synthesize PGI 2 (20.1±7.2 ng/10 6 cells, mean±SD) when stimulated with 20 µM sodium arachidonate for 2 min. PGI 2 production is inhibited by low-dose aspirin (5 µM); the t ½ of inactivation is 6.0±1.3 min (mean±SEM, n = 3). Thus, endothelial cell cyclooxygenase is as sensitive to aspirin as the enzyme in platelets. After 1 h incubation with aspirin, endothelial cell PGI 2 production was inhibited 50% by 2.1±0.4 µM aspirin and was inhibited 90% by 6.2±0.9 µM aspirin (mean±SEM, n = 4). When endothelial cells were incubated with 100 µM aspirin, washed, and recultured, their ability to synthesize PGI 2 returned to control levels in 35.6±1.0 h (mean±SEM, n = 4). Recovery of endothelial PGI 2 production after aspirin depended on de novo protein synthesis because treatment with cycloheximide (3 µg/ml) inhibited recovery by 92%.
A B S T R A C T Endothelial cells synthesize prostacyclin (PGI2), an unstable prostaglandin that inhibits platelet aggregation and serotonin release. Because cyclooxygenase, which is necessary for synthesis of PGI2, is inactivated by aspirin, we examined the effect of aspirin on PGI2 production by cultured human endothelial cells. Endothelial cells synthesize PGI2 (20.1+7.2 ng/106 cells, mean+SD) when stimulated with 20 ,uM sodium arachidonate for 2 min. PGI2 production is inhibited by low-dose aspirin (5 ,uM) ; the t1/2 of inactivation is 6.0+1.3 min (mean+SEM, n = 3). Thus, endothelial cell cyclooxygenase is as sensitive to aspirin as the enzyme in platelets.
After 1 h incubation with aspirin, endothelial cell PGI2 production was inhibited 50% by 2.1±0.4 ,uM aspirin and was inhibited 90% by 6 .2±0.9 ,uM aspirin (mean±SEM, n = 4). When endothelial cells were incubated with 100 uM aspirin, washed, and recultured, their ability to synthesize PGI2 returned to control levels in 35.6±1.0 h (mean±SEM, n = 4). Recovery of endothelial PGI2 production after aspirin depended on de novo protein synthesis because treatment with cycloheximide (3 jug/ml) inhibited recovery by 92%.
These results indicate that although endothelial (4) , and this is the basis for the use of aspirin as an antithrombotic agent. However, cyclooxygenase is also required for PGI2 synthesis from arachidonate so that inhibition of endothelial cell cyclooxygenase would decrease endothelial cell PGI2 production and might promote thrombosis. Because aspirin is now commonly used in the treatment ofthrombo-embolic disorders, we have examined the effect of aspirin on endothelial cell PGI2 production.
In this paper we show that although endothelial ' Abbreviation used in this paper: PGI2, prostacyclin.
)r Clinical Investigation, Inc., 0021-9738/79/03/0532/04 $1.00 (5), and used when conifluent. Cell counits in dishes used on a given day varied by <15%.
Treatment of endothelial cells with aspirini. Aspirin (Sigma Chemical Co., St. Louis, MIo.) stock solutions (0.1 Mt in absolute ethanol) were always freshly preparedl and sterilized by filtration. Before addition to endothelial cells, the aspirin was diluted with sterile water and 0.01 vol of diluted aspirin solution added to the culture mediumii to achieve the desired final concentration. The endothelial cells were incubatedl in 5% CO2 at 37°C for varying periods of time after which the culture medium was removed and the cells washed twice with Buffer A (10 mM Hepes pH 7.3 at 37°C, 150 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1 mNM MgCl2, 5.5 mM glucose). The cells were then either assayed immediately for PGI2 production or washed and recultured for additional time periods and then assayed. Control endothelial cell monolayers treated with 0.1% ethanol alone were included in each series of experiments. Ethanol at this concentration had no effect on PGI2 synthesis.
Platelet preparations. Washed platelet suspensions for the thrombin release assay (see below) were prepared as previously described (3).
Assay for PGI2 production. Monolayers of eindothelial cells were washed twice with Buffer A and then covered with 1 ml of Buffer B (15 mM Tris HCI pH 8.6, 140 mM NaCl, 5.5 mM glucose), which preserves PGI2 activity (6) . Sodium arachidonate (final concentration, 20 ,uM) was then added and the monolayer incubated for 2 min at 37°C. Buffer B was then removed and either assayed immediately for PGI2 or frozen at -70°C until assayed. PGI2 activity was measured by quantitating the release of [14C]serotonin from prelabeled, washed, aspirin-treated platelet suspensions stimulated by thrombin in the presence or absence of authentic PGI2 or supernatant fluids containing PGI2. This assay system is a modification of the method of Baenziger et al. (6) and has been described previously (3) . PGI2 (a gift of Dr. John Pike, Upjohn Co., Kalamazoo, Mlich.) standards ranging from 0.1 to 100 nM were included in all experiments. Because the percent change in thrombin concentration producing 50% of maximal serotonin release (AT5O) varied in a dose-response fashion with PGI2 concentration, a curve of AT50 vs. log PGI2 was plotted and used to convert our AT50 data to PGI2 concentration.
Cycloheximide inhibition of the recovery of PGI2 production. Endothelial cells were incubated with 100 /.LM aspirin for 1 h, washed, and cultured for 18 h with cycloheximide (0.1, 1, or 3 jig/ml) (Sigma Chemical Co.). The cells were then assayed for PGI2 production and compared to cells processed in parallel in the absence of cycloheximide.
RESULTS
Time-course of inhibition of endothelial cell PGI2 production by aspirin. Endothelial cells stimulated for 2 (1 ml) of 28.2+14.7 nMI (mean±SD). Iniactivationi of endothelial cell cyclooxygenase by aspirini was meeasured as the reduction in PGI2 synthesis observed after stiimiulation with arachidonate (20 ,utM) for 2 min.
When endothelial cells were exposed to 5 gN1 aspirin for varying periods of time, PGI2 productioin rapidly declined (Fig. 1) . After 5 min of aspirin exposure PGI2 production fell to 36% of conitrol values, and after 1 h endothelial cell PGI2 productioin was <3% of control.
Because a plot of log (PGI2 ,=,/PGI2 ,=,) vs. time was linear for the first 20 min, the experimiienit initially followed pseudo first order kinetics for the acetylation reaction. WVith calculations similar to those of Burch et al. (7), the t112 of decrease of endothelial cell PGI2 production in the presenice of 5 ,u 1 aspirin was 6.0+ 1.3 min (mlean+SEM, n = 3), and the rate constant for the inhibition of PGI2 production by 5 levels by 35 h. Data obtained from curves of experiments such as those seen in Fig. 3 showed that after a 1 h incubation with 100 ,uM aspirin, endothelial cell PGI2 production returned to control levels in 35.6± 1.0 h (mean±SEM, n = 4). In three additional experiments in which recovery was monitored from 0 to 24 h, recovery curves were similar to those seen in Fig. 3 . By extrapolation these curves yielded an estimated recovery time of 37.6±4.9 h (mean±SEM, n = 3) which is consistent with the 36-h recovery time obtained in our other experiments. Resumption of endothelial cell PGI2 production after inhibition by aspirin was dependent on new protein synthesis. Cycloheximide inhibited the recovery of PGI2 production in a dose-related fashion; thus cycloheximide (3 ug/ml) inhibited recovery of PGI2 production by 92%. DISCUSSION Pharmacologic studies in man have shown that 650 mg of aspirin given orally will yield plasma aspirin levels of 128 ,uM at 10 min, 56 ,M at 25 min, and 18 ,M at 1 h (8). Our data (i.e., 6.2 ,uM aspirin for 1 h inhibits endothelial cell PGI2 production by 90%) indicate that endothelial cell PGI2 production is promptly inhibited by doses of aspirin comparable to those employed clinically. This is also true of platelet thromboxane A2 production (7) . It thus appears that endothelial cell and platelet cyclooxygenases are equally sensitive to aspirin inhibition. Endothelial cells begin to regain their ability to produce PGI2 as soon as aspirin is removed (Fig. 3) and recover fully by -36 h. In marked contrast, however, platelets never regain cyclooxygenase activity after aspirin because acetylation of the enzyme is not reversible (7) . The platelet cyclooxygenase, which becomes measurable 48 h after aspirin, represents that present in newly formed platelets (7) . Thus, during the first 48 h after aspirin treatment, endothelial cells can produce PGI2, whereas platelets cannot produce thromboxane A2. Recovery of endothelial PGI2 production after aspirin reflects new protein synthesis inasmuch as it is inhibited by cycloheximide.
In the early stages of recovery from aspirin inhibition, endothelial cell PGI2 production may be <10% of normal (i.e., 10% of 28.2 nM or 2.8 nM in our culture system). The surface:volume ratio of the human vascular system (1,000 m2/3,500 ml = 2.86 x 103 cm2/ ml)2 is much greater than this ratio in a 35-mm Petri dish (9.6 cm2/1 ml 9.6 cm2/ml). Thus in vivo production of PGI2 at 10% of maximum could theoretically yield a peak blood PGI2 concentration of -830 nM (2.8 nM x 2.86 x 103/9.6). In vitro, such levels of PGI2 have a profound inhibitory effect on platelet behavior. For example, 1.4 nM PGI2 fully inhibited thrombus formation, and 57 nM PGI2 inhibited platelet adhesion by 56% when human blood was exposed to rabbit aorta subendothelium (10) . Furthermore, 47 nM PGI2 caused a half-maximal increase in platelet cyclic AMP to a level of -12 times basal level (11) when only a doubling of cyclic AMP was needed to inhibit platelet aggregation (12) . Similarly, we have reported that 0.1 nM PGI2 completely inhibited platelet aggregation in platelet-rich plasma induced by threshold levels of arachidonic acid (3). Thus, in man and experimental animals even a small fraction of the productive capacity for PGI2 in normal blood vessels should result in more than enough PGI2 to inhibit platelet function.
Recent animal studies support our contention that the effect of aspirin on endothelial cyclooxygenase is of brief duration. In rabbits, PGI2 mediated decrease in thrombus size after standardized vascular injury was observed as soon as 2.5 h after infusion of aspirin (200 mg/kg) (13) . Also, in rats given lysine acetylsalicylate (200 mg/kg), PGI2 production in veins returned to 51% of control in 24 h and to normal levels in 48 h (14) .
In summary, endothelial cell PGI2 synthesis is inhibited by low doses of aspirin, but recovery to control levels occurs by 36 h. The ability of endothelial cells in normal blood vessels to produce PGI2 seems to be far in excess of that needed to inhibit platelet function. Our data thus suggest that aspirin as used in clinical practice will not paradoxically promote thrombosis. We do, however, suggest that in patients with normal platelet turnover, aspirin administration be limited to once a day.
